Business
Notice of Allowance for US Patent
Notice of Allowance for US Patent.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \n Allowance of US Patent on Isobaric Tandem Mass Tags \n\n TMT® Launch at ASMS \n\nCOBHAM, England (June 12, 2008) - Proteome Sciences plc (\"Proteome Sciences\")\nis pleased to announce that the USPTO has issued a Notice of Allowance for its\nUS patent application in isobaric mass labelling for its tandem mass tags (TMT®) entitled\n\"Mass Labels\" Serial No. 10/489/341 (TMT2). The Notice of Allowance completes\nthe final stage of patent examination and represents the form in which the\npatent will be granted. This follows grants of the corresponding cases in\nEurope, Australia and Canada. Issued patents are already granted for TMT1 in\nthe USA, Europe and other main jurisdictions.\n\nThermo Fisher Scientific, Inc. launched a range of TMT® products at the ASMS\nmass spectrometry meeting in Denver, USA last week less than two months after\nobtaining the exclusive license for isobaric tandem mass tag technology from\nProteome Sciences.\n\nThe high profile launch started with a well attended user meeting and was\naccompanied and endorsed by 8 scientific posters/papers presented by Proteome\nSciences and a number of global scientific leaders in the field, confirming the\nutility and performance of TMT/isobaric mass tags across a broad range of\ndifferent applications. These have been posted onto our website \nwww.proteomics.com.\n\nCommenting on the US Notice of Allowance and the TMT® launch. Christopher\nPearce, CEO of Proteome Sciences said:\n\n\"We are delighted to have received the Notice of Allowance for TMT2 in the US.\nThe patenting process for TMT1 and TMT2 is largely complete in the major\njurisdictions and we can look forward to seeing Thermo Fisher exploiting the\nconsiderable opportunities from isobaric mass tags to deliver rapid biomarker\nand assay solutions.\n\nTMT® provides fast, flexible and cost effective workflows seamlessly from\nbiomarker discovery, through validation to clinical development and will\naccelerate the utility and application of biomarkers in drug development and\ndiagnostics to make personalised medicine a reality\"\n\n Ends \n\nAbout Proteome Sciences:\n\nProteome Sciences plc (LSE : PRM) is a global leader in applied proteomics,\nusing high sensitivity proprietary techniques to detect and characterise\ndifferentially expressed proteins in diseases for diagnostic, prognostic and\ntherape...